p.L1612P, a Novel Voltage-gated Sodium Channel Nav1.7 Mutation Inducing a Cold Sensitive Paroxysmal Extreme Pain Disorder by Suter, Marc et al.
Anesthesiology, V 122 • No 2 414 February 2015
P AROXYSMAL extreme pain disorder (PEPD) is a chronic, genetically determined disease, character-
ized by episodes of excruciating pain and flushing upon 
benign mechanical or heat stimuli mostly in rectal, ocular 
or submandibular regions.1–4 Additional symptoms include 
extension of pain to the lower limbs, bradycardia, tonic non-
epileptic seizures and syncope. PEPD is caused by heterozy-
gous mutations in the sodium channel, voltage-gated type IX, 
α-subunit gene (SCN9A) which encodes the Nav1.7 sodium 
channel.4 Disease-causing mutations lead to a channel gain-
of-function through depolarizing shift of voltage-dependence 
of inactivation of Nav1.7 sometimes associated with persis-
tent current, which increases excitability of sensory neurons. 
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ABSTRACT
Background: Mutations in the SCN9A gene cause chronic pain and pain insensitivity syndromes. We aimed to study clinical, 
genetic, and electrophysiological features of paroxysmal extreme pain disorder (PEPD) caused by a novel SCN9A mutation.
Methods: Description of a 4-generation family suffering from PEPD with clinical, genetic and electrophysiological studies 
including patch clamp experiments assessing response to drug and temperature.
Results: The family was clinically comparable to those reported previously with the exception of a favorable effect of cold 
exposure and a lack of drug efficacy including with carbamazepine, a proposed treatment for PEPD. A novel p.L1612P 
mutation in the Nav1.7 voltage-gated sodium channel was found in the four affected family members tested. Electro-
physiologically the mutation substantially depolarized the steady–state inactivation curve (V1/2 from −61.8 ± 4.5 mV to 
−30.9 ± 2.2 mV, n = 4 and 7, P < 0.001), significantly increased ramp current (from 1.8% to 3.4%, n = 10 and 12) and 
shortened recovery from inactivation (from 7.2 ± 5.6 ms to 2.2 ± 1.5 ms, n = 11 and 10). However, there was no persistent 
current. Cold exposure reduced peak current and prolonged recovery from inactivation in wild-type and mutated channels. 
Amitriptyline only slightly corrected the steady–state inactivation shift of the mutated channel, which is consistent with 
the lack of clinical benefit.
Conclusions: The novel p.L1612P Nav1.7 mutation expands the PEPD spectrum with a unique combination of clinical 
symptoms and electrophysiological properties. Symptoms are partially responsive to temperature but not to drug therapy. 
In vitro trials of sodium channel blockers or temperature dependence might help predict treatment efficacy in PEPD. 
( Anesthesiology 2015; 122:414-23)
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What We Already Know about This Topic
•	 Mutations of the sodium ion channel SCN9A gene have been 
associated with syndromes of both heightened and dimin-
ished pain sensitivity
•	 Those mutations supporting channel over activity and height-
ened pain sensitivity often respond to sodium ion channel 
blocking molecules
What This Article Tells Us That Is New
•	 A new mutation, p.L1612P, was found in four family members 
suffering from Paroxysmal Extreme Pain Disorder
•	 The mutant ion channel possesses unique electrophysiologi-
cal characteristics, and a pharmacological profile distinct from 
other known mutations
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Less than 20 families with PEPD have been reported world-
wide.5,6 Other mutations in SCN9A cause disorders such as 
congenital insensitivity to pain, erythromelalgia, and small-
fiber neuropathy and participate in painful not paroxysmal 
pain syndromes.7,8 Inherited erythromelalgia (IEM) induc-
ing mutations also increase excitability of sensory neurons 
but classically through a hyperpolarizing shift of the activa-
tion. Typical symptoms of affected patients are peripheral, 
bilateral severe burning pain of affected extremities associ-
ated with erythema, triggered by warmth, stress and exhaus-
tion and often relieved by cooling of the affected sites.9 
Nonpharmacological measures to prevent or treat painful 
attacks such as immersion in ice-cold water were mostly 
described in patients suffering from erythromelalgia.10 The 
therapeutic effect of cold is not described in PEPD. The two 
diseases therefore present with distinct electrophysiological 
and clinical hallmarks. One p.A1632E mutation combines 
the stereotypical characteristics of both diseases with elec-
trophysiological demonstration of the depolarizing shift of 
steady–state inactivation as well as the hyperpolarizing shift 
of activation seen in PEPD and IEM, respectively. Cooling 
improves the patient’s symptoms.11
The sodium channel blocker carbamazepine is the treat-
ment of choice for PEPD;4 however it fails to alleviate pain 
in some patients. Therefore, other therapeutic options 
need to be investigated and the electrophysiological and 
clinical features of each individual mutation should be 
taken into account.
Amitriptyline which is a first line drug for neuropathic 
pain12 blocks the Nav1.7 sodium channel.13 Other sodium 
channel blockers such as lidocaine have been used success-
fully in neuropathic pain of different etiologies14–17 including 
Nav1.7 mutations.18 However, administration of lidocaine 
requires an intravenous line and despite some patients 
reporting prolonged improvement after the infusion,16 an 
orally available sodium channel blocker is preferable for long 
term therapy. Mexiletine, the oral drug usually used after 
positive intravenous lidocaine trials,18,19 is not available in 
many countries and is only marketed for cardiac conditions. 
Amitriptyline is sometimes used as an alternative following 
lidocaine.20 Herein, we report detailed clinical and genetic 
investigation of a family with PEPD caused by a novel muta-
tion in the SCN9A gene; in vitro electrophysiological evi-
dence of pathogenicity; and effects of amitriptyline and cold 
exposure both at the clinical and electrophysiological levels.
Material and Methods
Clinical and Genealogical Investigation
The family originates from Portugal, with several members 
now living in Switzerland, Spain, and Australia. Partial clinical 
data on selected members were previously published (Family 
13 in Fertleman et al.).6 Patients and at-risk family members 
were reinvestigated by means of a semistructured interview, 
either in person or over the phone. Data collected included 
demographic information, as well as details on the nature, 
distribution, and triggering factors of symptoms. Those 
affected individuals who were available underwent thorough 
neurological examination (Thierry Kuntzer, Christian Wider, 
Marc R. Suter); nerve conduction studies were performed on 
the index patient. The study was accepted by the institutional 
review board of the Canton de Vaud, Lausanne, Switzerland. 
All individuals enrolled provided written informed consent.
Genetic Study
DNA was extracted from lymphocytes using standard meth-
ods. Samples from all four available affected individuals 
underwent sequencing of all exons and exon–intron bound-
aries of the SCN9A gene. Methods employed included poly-
merase chain reaction amplification and Sanger sequencing 
(primers available upon request). Following identification 
of the novel SCN9A p.L1612P mutation, samples from all 
available family members were genotyped using the same 
methods. Ninety-two Swiss adults seen at the genetics ser-
vice for other disorders without any history of chronic pain 
were also assessed for presence of the p.L1612P mutation.
Plasmid and Cell Line
The p.L1612P substitution was inserted into a plasmid con-
taining the human Nav1.7 insert using QuikChange XL II 
site directed mutagenesis kit (Agilent Technologies, Basel, 
Switzerland). Human embryonic kidney 293 cells were 
cultured in Dulbecco’s Modified Eagle Medium (GIBCO 
cat#41965 039, Invitrogen, Merelbeke, Belgium) supple-
mented with 10% fetal bovine serum, L-Glutamine 4 mM 
(GIBCO cat#25030 024, Invitrogen, Merelbeke, Belgium) 
and gentamicin 0.02 mg/ml (Invitrogen cat# 15750-037, 
Paisley, Scotland, United Kingdom). Transient transfection 
of either wild-type (WT) human Nav1.7 or L1612P mutant 
plasmid associated with three plasmids with inserts for β1 
and β2 subunits of sodium channels and green fluorescent 
protein, was performed using jetPEI (Polyplus, Illkirch, 
France), with the ratio α:β1:β2:green fluorescent protein 
being 20:2:2:1 as previously described.21 One day after 
transfection, cells were plated to be recorded at 48 h.
In Vitro Electrophysiology
Measurements were made using pClamp software, version 
10.3, and a multiclamp 700B amplifier (Molecular Devices, 
LLC, Sunnyvale, CA) at room temperature, if not otherwise 
specified. The sampling rate was 100 kHz with a low pass Bes-
sel filter at 10 kHz. Data were smoothed and analyzed using 
Clampfit software version 10.3.1.5 (Molecular Devices, 
LLC), and KaleidaGraph (Synergy Software, Reading, PA).
Whole-cell Patch clamp recordings were conducted 
using an internal solution containing (in mmol/L) CsCl 60, 
Cesium aspartate 70, EGTA 11, MgCl2 1, CaCl2 1, HEPES 
10, and Na2-adenosine triphosphate 5, pH adjusted to 7.2 
with CsOH; and an external solution containing NaCl 130, 
CaCl2 2, MgCl2 1.2, CsCl 5, HEPES 10, and glucose 5, 
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pH adjusted to 7.4 with CsOH. Holding potential was 
−100 mV. The values were not corrected for liquid junc-
tion potential. Pipette resistance was ranging from 2 to 
7 MOhm. Once whole cell configuration was obtained, 
pipette and cell capacitance were minimized using the 
muticlamp commander. To reduce voltage errors, 80–90% 
series resistance compensation was applied. Only data from 
cells having stable access resistance over the duration of the 
experiment were used. Cells for which signs of poor volt-
age-clamp control, such as delayed inflections of the current 
or discontinuities in the peak INa versus Vm curve were not 
analyzed. Protocols are shown as insets in the figures. The 
experimenter was not blinded during the electrophysiologi-
cal studies. Everything was done to avoid bias. Cell culture 
and transfection were performed in parallel for both geno-
type and cells containing the plasmid from the two geno-
types were alternatively patched.
Peak currents were measured from the activation pro-
tocol. The linear ascending segment of the current–voltage 
relationship was used to estimate the reversal potential for 
each trace before converting peak current to conductance 
and obtaining the voltage–dependent activation curve. Volt-
age-dependence of activation and steady–state inactivation 
curves were individually fitted with Boltzmann relationships, 
y(Vm) = 1/(1 + exp[(Vm–V1/2)/K]) in which y is the normal-
ized current or conductance, Vm is the membrane potential, 
V1/2 is the voltage at which half of the channels are activated 
or inactivated and K is the slope factor. The decaying phase 
of current elicited in the activation protocol was plotted as 
a single exponential (I= A exp[−t/τ] + C). For ramp current 
data were reduced by a factor of 200 with clampfit and corre-
lated to peak current of the same cell. The t1/2 value of recov-
ery from inactivation was calculated by interpolation from a 
linear relation between the 2 points juxtaposing half recov-
ery (y1 < 0.5 < y2), using the relation x = [0.5−(y1x2−y2x1)/
(x2−x1)]×(x2−x1)/(y2−y1).13 For slow inactivation the curve 
was fitted with a Boltzmann y = Imin + (Imax−Imin)/1 + 
exp((V50-X)/slope).
For Drug Testing. Amitriptyline (A8404) was purchased 
from Sigma (Buchs, Switzerland). Cells were perfused with 
extracellular medium until stable recordings were obtained 
(predrug). Amitriptyline was then perfused until stabiliza-
tion of the peak current, followed by the recording protocol 
detailed above.
To assess the effect of temperature cells were perfused 
at 15°C and 25°C using a temperature controller (Warner 
Instrument TC-344B, Hamden, CT). Recordings were 
performed whenever the stable desired temperature was 
obtained. Approximately 60% of the cells reaching whole 
cell configuration passed through the two-temperature pro-
tocol and half of these recordings could be analyzed.
Statistical Analysis
Data are presented as mean ± SD and were analyzed using 
two-tailed Student’s t test to compare V1/2, peak current, 
and t1/2 of recovery (paired for drug and temperature effect). 
Two-way analysis of variance was performed to examine 
decay curve, followed by Bonferroni’s correction for multiple 
testing. P < 0.05 was used as the level of significance. No 
power calculation was performed; our sample size was based 
on previous experiment.13 Statistical analysis was performed 
on GraphPad Prism, version 5.03 (GraphPad Software, La 
Jolla, CA).
Results
Clinical and Genealogical Characteristics
The family tree is presented (fig. 1A), showing seven affected 
individuals (two women) over four generations, with three 
patients examined directly, and DNA samples collected 
from four affected and three unaffected family members 
(individuals with * in fig. 1A). Clinical characteristics are 
summarized in figure 1B. Briefly, symptoms began in early 
infancy (range: from 1st day of life to 1 yr), with all patients 
having paroxysmal pain and flushing in the rectal/buttocks 
area and in the lower limbs, and two patients in the ocular 
and submandibular regions (III.2, IV.1). One patient also 
had symptoms in the upper limbs (IV.1). Triggers included 
light touch such as changing diapers, trauma, defecation and 
warm temperature. Strategies employed by the patients to 
shorten/abort the attacks included immersing themselves in 
ice-cold water. The favorable effect of cold water exposure led 
to major daily life adaptations such as presence of icy water 
bathtubs at school and a mechanical device to lift patients 
into the bathtub at home. In addition to pain and flushing, 
the index patient (III.2) described episodes when she would 
present with persistent weakness in the lower limbs for hours 
or even days after an attack, sometimes requiring hospitaliza-
tion. She presented around the age of 1 yr with episodes of 
loss of consciousness that prompted investigations for epi-
leptic seizures or cardiac arrhythmia. The clinical diagnosis 
of PEPD was only established later in her affected son. Gen-
eral neurologic examination was normal; motor and sensory 
nerve conduction studies were normal in the median and 
ulnar nerves in the index patient, and latency measurement 
of myoelectric deep tendon (T) reflex responses from soleus 
and rectus femoris muscles was also normal22 (the patient 
did not tolerate electrical shocks in the lower limbs for fear 
of triggering a painful attack). Carbamazepine was tried in 
two patients (III.2, IV.1). Patient III.2 reached 1,200 mg/d 
of carbamazepine but suffered from side effect (loss of bal-
ance, impairment in language and vision). Only minor ben-
efit was found in patient IV.1. Amitriptyline and pregabalin 
proved ineffective in the index patient.
Genetic Study
Sequencing of the SCN9A gene identified a novel c.4835T>C 
(p.L1612P) mutation in all four available affected individu-
als but not in the three at-risk unaffected family members, 
indicating perfect cosegregation with disease. In addition, 
Anesthesiology 2015; 122:414-23 417 Suter et al.
PAIN MEDICINE
the c.4835T>C mutation was not found in 92 healthy con-
trols of Swiss descent. Further supporting pathogenicity is 
the fact that the non-synonymous mutation lies in close 
vicinity to other previously reported pathogenic SCN9A 
mutations, within a region highly conserved across species.
In Vitro Study of the Mutated Channel
p.L1612P Displays Slower Inactivation Kinetics. We ana-
lyzed the decay of sodium current (entry into the fast inac-
tivated state) with a single exponential plotted from the 
current peak to the end of a 100 ms pulse at voltage steps 
from 0 to +30 mV. An example is shown in figure 2A and 
average time constant of decrease (τ) is shown against 
voltage in figure 2B. We observed a slower decay of cur-
rent in the p.L1612P mutant compared to the WT. Decay 
rates were 1.28 ± 0.63 (WT) and 3.27 ± 0.70 ms (mutant) 
(P = 0.00014, n = 6 for WT and n = 8 for mutant) after a sin-
gle depolarization at 10 mV. Mean residual current was mea-
sured 20, 50, and 100 ms after the peak. Figure 2C shows the 
percentage of peak current at each time-point with a signifi-
cant increase between WT and mutant channels 20 ms after 
the peak. Of note, at 50 and 100 ms the persistent current 
recorded in cells expressing in WT and p.L1612P channels 
were not different and of very small value.
p.L1612P Shifts Voltage-Dependence of Activation and 
Steady–State Inactivation. Activation curves were obtained 
using 10 ms steps to potentials from −80 to +15 mV in 5 
mV increments from the −100 mV holding potential. We 
observed a depolarizing shift in the activation curve of 
the mutant with a displacement of V1/2 from −9.0 ± 7.2 to 
0.0 ± 1.9 mV (P = 0.028, n = 13 for WT and n = 11 for 
p.L1612P, fig. 3A). Mean peak current density measured 
Fig. 1. Pedigree and clinical data. (A) Index patient (arrow) and pedigree of her family: *DNA sample available; squares: males; 
circles: females; black: affected; white: unaffected. (B) Clinical characteristics of family members available for the genetic 
study. + = present; - = absent; AMI = amitriptyline; CBZ = carbamazepine; F = flushing; LL = lower limbs; NA = not applicable; 
O = ocular; PGB = pregabalin; PPX = pramipexole; R = rectal/buttocks; RL = restless-legs symptoms; SM = submandibular; 
U = unavailable; UL = upper limbs. *No details were available for patient II.4 who only donated a blood sample.
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from the current–voltage protocol were not different 
(316.2 ± 266.9 pA/pF for WT and 274.5 ± 278.7 pA/pF 
for p.L1612P, n = 15 and 19, P = 0.67). For steady–state 
fast inactivation curve (SSI) 500 ms prepulses ranging from 
−130 to +5 mV followed by a 20 ms pulse to 0 mV were 
applied. The p.L1612P substitution largely shifted SSI to 
more depolarized values with a difference in V1/2 of 30.9 mV 
(−61.8 ± 4.5 for WT and −30.9 ± 2.2 mV for p.L1612P, n = 
4 and 7, P < 0.001, fig. 3A). The p.L1612P mutant showed 
full inactivation at the end of the SSI protocol.
Recovery from Inactivation Is Hastened by the p.L1612P 
Mutation. To measure recovery from fast inactivation, we 
used a double pulse protocol with varying interpulse inter-
val and plotted the ratio of the second to the first pulse 
to the interval. The t1/2 of recovery from inactivation was 
significantly faster in cells expressing the mutant channels 
(2.2 ± 1.5 and 7.2 ± 5.6 ms for p.L1612P and WT, n = 10 and 
11, P = 0.013, fig. 3B).
The p.L1612P Mutation Increases Ramp Current. To 
assess the theoretical increase in window current seen 
when superposing activation and SSI curves, we looked 
at the response of WT and mutant channels to slow ramp 
depolarization from −100 to +20 mV at a rate of 0.2 
mV/ms. Ramp current was normalized to the peak cur-
rent. We observed a significant difference (P = 0.0018) 
in maximum ramp current between WT (1.8 ± 1.4%, n = 
10) and p.L1612P channels (3.4 ± 0.7%, n = 12) (fig. 3C). 
The peaks of ramp current were at −7.4 [−37.2 to +1.2] 
and −8.4 [−12 to +2] mV (median [range]) for WT and 
mutant channels (P = 0.2).
The p.L1612P Substitution Does Not Alter Voltage-depen-
dence of Slow Inactivation. To study voltage-dependence 
of slow inactivation, we used a 30 s duration prepulse at 
voltages ranging from −120 to +30 mV followed by a short 
100 ms pulse to −120 mV in order to let the channels recover 
from fast inactivation and a 50 ms test pulse to 0 mV to acti-
vate the available channels. We did not observe any differ-
ence in V1/2 of slow inactivation (−39.6 ± 3.3 and −35.7 ± 7.4 
mV, n = 8 and 12 for WT and p.L1612P, P = 0.19, fig. 3D) 
and no difference in the fraction of current resistant to slow 
inactivation (29 ± 7% vs. 33 ± 9%, P = 0.27).
Amitriptyline Affects WT and p.L1612P. Amitriptyline at 
a concentration of 10 μM induced a similar reduction in 
peak current in WT and mutant channels (33.9 ± 8.5% and 
30.0 ± 7.6%, normalized traces in fig. 4A). Amitriptyline 
did not influence the entry into the fast inactivated state 
(P = 0.36 and 0.33, n = 5 and 4, for the treatment fac-
tor in two-way analysis of variance for WT and p.L1612P, 
fig. 4B). Amitriptyline had no effect on activation curves of 
both WT and p.L1612P channels (fig. 4C). Amitriptyline 
shifted SSI to more hyperpolarized values in WT (−7.96 
mV) and mutant channels (−8.51 mV) (fig. 4D). Amitrip-
tyline inhibited the recovery from fast inactivation, pro-
longing t1/2 of recovery (fig. 4E). Amitriptyline did reduce 
peak ramp current in WT but did not reach significance in 
p.L1612P (fig. 4F).
Both p.L1612P and WT Currents Are Altered by Cold Tem-
perature. Cooling the recorded cells from 25° to 15°C 
reduced peak current density for both WT and p.L1612P 
mutants (respectively 45.4% and 35.9%, fig. 5, A and B), 
and slowed current decay over a large voltage range (fig. 5C). 
Voltage-dependence of activation curves was shifted to more 
depolarized potentials (fig. 5D). V1/2 of SSI was not influ-
enced by the change in temperature (fig. 5E). Recovery from 
inactivation was slowed at 15° compared to 25°C (fig. 5F). 
The ramp current was slightly increased for WT but not for 
the mutant channel.
Discussion
We report a novel p.L1612P mutation in the SCN9A gene in a 
family with PEPD. Overall, clinical features were comparable 
Fig. 2. Current characteristics of WT and mutant channels. 
(A) Recordings of both WT and p.L1612P mutant channels, 
normalized to the same peak current. (B) Slower current de-
cay of the p.L1612P channel. (C) No difference in persistent 
current is observed between the WT and p.L1612P channel 
at 50 and 100 ms and its value reaches below 1% at 100 ms 
after the peak. LP = p.L1612P; WT = wild type (**P < 0.01 and 
***P < 0.001).
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to those reported in other families suffering from PEPD with 
the exception of symptom relief by cold exposure, presence of 
pain in the upper limbs in one patient and long-lasting lower 
limb weakness after paroxysmal episodes of pain.6 Careful 
clinical examination and nerve conduction studies failed to 
provide an explanation for limb weakness beyond fear of pain 
reactivation. Clinical response to carbamazepine, amitripty-
line and pregabalin was absent or limited. Genetic findings 
demonstrated a novel mutation in SCN9A, with conclusive 
genetic and in vitro evidence of pathogenicity. Electrophysi-
ologically the p.L1612P mutant channel displayed a large 
depolarizing shift of the SSI curve, increased ramp current, 
faster recovery from inactivation, and slowing of fast inac-
tivation without persistent current, all together suggesting a 
channel gain of function and cell hyperexcitability.
Voltage-gated sodium channels comprise four domains 
(DI–DIV) of 6 transmembrane segments (S1–S6) each, 
with Nav1.7 residue Leu1612 being located within the S4–
S5 linker of DIV. Upon membrane depolarization Nav1.7 
channels are activated allowing sodium entry into the cells; 
they then enter into inactivated states before returning to the 
closed state upon repolarization of the membrane. Fast inac-
tivation relies on the interaction between the Ile–Phe–Met 
(IFM) residues motif located between DIII and DIV and the 
S4–S5 linker of DIV.23,24 Most of the previously described 
PEPD-causing mutations were found to be located either 
within the IFM motif or in the S4–S5 linker of DIII or DIV, 
as is the case for p.L1612P.
The magnitude of the SSI depolarizing shift with 
p.L1612P channels (30.9 mV) is larger than in previously 
reported mutations, with the exception of neighboring 
p.G1607R (31.5 mV).5 p.L1612P is the second PEPD-caus-
ing mutation to induce a depolarizing shift of the activation 
curve; only p.G1607R displays a 4.3 mV depolarizing shift (9 
mV in the present study).5 Other PEPD-causing mutations 
do not affect activation properties except for the hyperpolar-
izing shift of p.A1632E whose carriers also exhibited IEM 
symptoms.11 It has been proposed that Nav1.7 is responsible 
for triggering action potential from subthreshold oscilla-
tions.25 This may be because of the window current, which 
consists of the voltage values under the intersection of activa-
tion and SSI curves where a portion of channels remain open 
at steady–state. The window current in p.L1612P mutants 
is increased by the SSI depolarizing shift despite activation 
shift. Experimentally window current is observed through 
the response to a slow ramp stimulation which is increased 
here. Mutation in the IFM motif displays ramp currents 
of 4% (p.I1461T), DIII S4–S5 mutations of 5 and 6% 
(p.V1298F and p.V1299F) and DIV S4–S5 linker muta-
tions of 4.2 and 7.0% (p.A1632E and p.M1627K).11,24,26 
Interestingly, the neighboring p.G1607R mutation shows a 
much wider ramp current of 15.7% (ramp speed of 0.24 
compared to our 0.2 mV/ms).5 Response to ramp stimula-
tion has occasionally been reported to include two peaks 
depending on the rate of ramp or on persistent current.27 
Our ramp current corresponds to the rate of ramp because 
Fig. 3. Electrophysiological properties of WT and mutant channels. (A) The p.L1612P mutation significantly shifts activation and 
SSI properties towards depolarization; the amplitude of shift is much greater for the SSI. The mutant p.L1612P channel displays 
shorter recovery from inactivation (B) and increased ramp current (C) but no difference in V1/2 of slow inactivation (D). ACT = 
activation; LP = p.L1612P; SSI = steady–state inactivation; WT = wild type. Stimulation protocols are shown as insets.
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it increased to 19.2% for p.L1612P when stimulation rate 
was faster (1.2 mV/ms) (data not shown) and because no 
persistent current was observed.
Slowing of fast inactivation, reflected as a slower current 
decay, was reported in all previously examined PEPD-caus-
ing mutations; however lack of persistent current appears to 
be a particular feature of the p.L1612P mutant. Fertleman et 
al. measured a persistent current even 100 ms after depolar-
ization in both p.I1461T and p.T1464I mutations.4 Apply-
ing 25 ms depolarizing pulses, Jarecki et al. found a 15% and 
8% persistent current for p.V1299F and p.I1461T.26
The p.L1612P mutant channel shows complete fast 
inactivation, which contrasts with p.I1461T and p.T1464I 
displaying maximal inactivation levels of 54.7% and 
63.5%.4 This probably reflects the fact that both p.I1461T 
and p.T1464I affect the inactivation gate and are associ-
ated with more prominent persistent current. In mutations 
located within the S4–S5 linker of DIII, close to p.L1612P 
substitution of the present study, there was a 1.9% fraction 
of current remaining for p.M1627K, 6.3% for p.G1607R 
and about 4% for p.A1632E (value approximated from 
figure).4,5,11 Faster recovery from inactivation is reported in 
most PEPD mutations including p.L1612P. The effect on 
slow inactivation is comparable to that of the p.M1627K 
mutation, with no major change in V1/2 but a steeper volt-
age-dependence.26 Using the same stimulation protocol but 
Fig. 4. Effect of amitriptyline on channel properties. (A) Example of Na current induced by 0 mV depolarization at 1Hz frequency 
from a −100mV holding potential while changing amitriptyline concentration from 0 to 10 μM for both WT and p.L1612P channels 
(normalized traces). (B) Amitriptyline does not modify the pace of inactivation. (C) Amitriptyline does not change activation prop-
erties. (D) Amitriptyline shifts SSI towards more hyperpolarized values without fully counteracting mutation-induced depolarizing 
shift (V1/2 −58.43 ± 5.97 to −66.39 ± 5.01 mV, P = 0.0011, n = 5 for WT and −31.16 ± 2.53 to −39.67 ± 1.76 mV, P = 0.0015, n = 4 
for p.L1612P). (E) Amitriptyline prolongs recovery from inactivation from 10.0 ± 2.5 to 228.1 ± 90.4 ms for WT (P = 0.018, n = 4) 
and from 4.7 ± 2.3 to 247.3 ± 108.1 ms for p.L1612P mutant channels (P = 0.021, n = 4). (F) Amitriptyline decreased ramp current 
decrease of WT channel but not of p.L1612P (from 1.05 ± 0.31 to 0.78 ± 0.34%, P = 0.047, n = 5 for WT and from 4.08 ± 0.11 to 
3.32 ± 0.98%, P = 0.341, n = 3 for p.L1612P). AMI = amitriptyline; CTRL = control; LP = p.L1612P; WT = wild type. Stimulation 
protocols are shown as insets.
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a different intracellular patch solution, Estacion et al. showed 
a larger proportion of channels being resistant to inactiva-
tion in p.A1632E compared to WT channels.11 Jarecki et al. 
also showed alteration of slow inactivation for p.V1298F, 
p.V1299F and p.I1461T mostly because of the presence of 
two different kinetics in WT channels.24 Slow-inactivation 
properties are also altered in some SCN9A mutations present 
in patients suffering from idiopathic small fiber neuropathy.28 
In the I739N and I720K mutations, slow inactivation is mod-
ified without impairment of activation and fast-inactivation 
properties.7,28 Clinical features in idiopathic small fiber neu-
ropathy patients vary and are different from the prototypical 
characteristics of PEPD and IEM patients, indicating that the 
clinical expression of a mutation not only reflects its electro-
physiological properties but also other factors, such as epigen-
etic or environmental changes.7,28
Amitriptyline is a state-dependent sodium channel 
blocker which receptor overlaps with the local anesthetic 
receptor that is known to stabilize the inactivated state.29 
Overall, the effects of amitriptyline were similar in mutant 
Fig. 5. Effect of temperature changes on channel properties. (A) Example of Na current induced by 0 mV depolarization at 1Hz 
frequency from a −100mV holding potential while changing temperature from 15° to 25° for both WT and p.L1612P channels 
(normalized traces). (B) Temperature decrease reduces mean current density in both WT and p.L1612P ***P < 0.001, n = 21 and 
15). (C) The decay is slower at lower temperature (***P < 0.001 LP15° vs. LP25°, #P < 0.05, ###P < 0.001 WT15° vs. WT25°, 
n = 19 for WT and n = 14 for p.L1612P). (D) Cooling induces a small but significant shift of V1/2 of activation towards more hyper-
polarized values (WT: V1/2 from −4.64 ± 4.07 to −2.73 ± 3.48 mV, P = 0.002, n = 20; p.L1612P: V1/2 from −1.24 ± 4.11 to 1.09 ± 2.57 
mV, P = 0.002, n = 15). (E) No difference is seen in V1/2 of inactivation between 15° and 25° (WT: V1/2 from −55.52 ± 10.07 to 
−55.42 ± 9.63 mV, P = 0.96, n = 12; p.L1612P: V1/2 from −32.16 ± 5.45 to −36.19 ± 5.99 mV, P = 0.12, n = 7). (F) At 15° the 
 recovery from inactivation is slower with an increase in t1/2 from 3.18 ± 0.84 to 12.68 ± 3.94 ms for WT (P = 0.004, n = 5) and from 
1.48 ± 0.21 to 3.86 ± 0.88 ms for p.L1612P (P = 0.001, n = 6). The recovery of the mutant at 15° comes to the same value as for 
WT at 25°. LP = p.L1612P; WT = wild type. Stimulation protocols are shown as insets.
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and WT channels and consistent with previous findings.13 
Of note, the hyperpolarizing SSI shift induced by amitripty-
line was far from being large enough to compensate for the 
depolarizing shift induced by the mutation, hallmark of elec-
trophysiological change in PEPD inducing mutant, which 
might explain the lack of clinical benefit. Sodium chan-
nel blockers are used to treat chronic pain syndromes and 
there have been attempt to correlate in vitro effect of drugs 
to their clinical efficacy.19,30 Carbamazepine reduced persis-
tent current and was efficient clinically in persistent current 
harboring PEPD-causing mutations. In our case, the lack of 
persistent current can correlate to inefficiency of carbam-
azepine. Carbamazepine was said to be ineffective in eryth-
romelalgia,6 but meanwhile patients harboring p.V400M 
mutation were treated efficiently with this drug. Surprisingly 
the electrophysiological properties of this mutation do not 
show persistent current, but the expected hyperpolarizing 
shift in activation curve associated to an unusual depolariz-
ing shift of inactivation for IEM. Carbamazepine selectively 
shifts the SSI and activation curves from the mutant towards 
the WT values which could explain its effect.31 The shift 
in SSI of much higher amplitude of the current p.L1612P 
mutation could explain the lack of efficacy in our patient. 
Carbamazepine also was efficient in IEM in patient harbor-
ing I848T mutation,32 which again displays a depolarizing 
shift in SSI besides the hyperpolarizing activation shift.30
As no drug relieved pain but cooling improved symp-
toms in the affected members of the described family, we 
investigated the effect of temperature in vitro. This has not 
been extensively assessed in Nav1.7 channels with PEPD-
causing mutations because relief through cooling is char-
acteristically only seen in IEM. One previous report on 
the IEM causing p.L858F mutation showed that reducing 
temperature decreased current density, slowed deactivation, 
increased ramp current in both WT and mutant channels, 
and shifted activation V1/2 of WT channel in a depolariz-
ing direction.9 We also observed decreased current density, 
slower inactivation, depolarizing shift of activation and 
increased time to recovery, however with no change in V1/2 
of SSI when cooling from 25° to 15°. The relevance of the 
amplitude of the depolarizing shift in activation of respec-
tively, 1.91, and 2.33 mV for WT and p.L1612P channel 
on excitability is questionable.
One property that is regulated differentially between 
amitriptyline and cold is the slowing of inactivation kinet-
ics. A slower inactivation should lead to hyperexcitability 
but if prolonged, it could also impede the availability for 
subsequent opening by delayed recovery. Cold also slowed 
recovery from inactivation and shifted the 15° mutant chan-
nel value to the WT channel room temperature value. The 
normalization of this property alone cannot be sufficient to 
hinder pain as amitriptyline even slows it to a larger extent 
without relieving symptoms. The clinical benefit of cold ver-
sus amitriptyline could be explained by its combined modifi-
cation of biophysical properties of Nav1.7, but cold-induced 
pain relief might also be related to signal transduction or 
conduction changes independent of Nav1.7 channel.
Increased availability of patient genotyping and in vitro 
electrophysiology techniques may offer an opportunity for 
preclinical testing of drug efficacy in patients harboring 
SCN9A mutations.19 Amitriptyline could not restore SSI shift 
and window current to the values of the WT channel and was 
not effective in the index patient of the study. Similarly, while 
efficacy of carbamazepine in PEPD is probably linked to a 
reduction of persistent current4 the absence of such persis-
tent current in the p.L1612P mutant could explain the lack 
of efficacy of carbamazepine in this family. Cooling changes 
the biophysical properties of the channel differentially from 
the drug tested which might account for its pain relieving 
effect. Overall, the present study illustrates how preclinical 
testing may help avoid laborious drug trials in patients with 
genetically determined pain syndromes through selection of 
the best candidate drugs or physical therapy.
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